Home Blog of Signal Transduction Metabolism RUNX

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

RUNX

YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522

89 views | Dec 20 2023

The study reveals that transfer RNA-derived small RNAs, specifically tRF-GlyTCC, function as a constitutive tumor suppressor mechanism in primary bone cancer, attenuating pro-metastatic protein-RNA interactions by targeting RUNX2 via a shared sequence motif with YBX1, leading to the development of the therapeutic agent CADD522 with significant efficacy in reducing tumor progression and metastasis in PBC. [Read the Full Post]

Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease

79 views | Oct 03 2023

The novel RIPK2 inhibitor Zharp2-1 shows promising potential for the treatment of inflammatory bowel disease (IBD) based on its ability to effectively block RIPK2 kinase function, inhibit NOD-mediated signaling, and ameliorate colitis symptoms in preclinical studies. [Read the Full Post]